MKI67 and Wilson disease: Currently, the role of cytotoxic chemotherapy in advanced WD-NETs remains debated and predominantly considered in advanced NETs with high Ki-67 proliferation index and tumor burden, in a rapidly progressive disease, after failure of the other therapies, and/or when tumor size reduction by cytotoxic intervention is a therapeutic goal (4–6).